Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Dextromethorphan: cellular effects reducing neuronal hyperactivity

G Trube¹, R Netzer

¹Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

|January 1, 1994

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Factors associated with response after deep transcranial magnetic stimulation in a real-world clinical setting: Results from the first 40 cases of treatment-resistant depression.

European psychiatry : the journal of the Association of European Psychiatrists·2017

Same author

3-Phosphoglycerate dehydrogenase from Corynebacterium glutamicum: the C-terminal domain is not essential for activity but is required for inhibition by L-serine.

Applied microbiology and biotechnology·2002

Same author

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.

The Journal of pharmacology and experimental therapeutics·2002

Same author

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.

Bioorganic & medicinal chemistry letters·2001

Same author

Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels.

Arzneimittel-Forschung·2001

Same author

Screening lead compounds for QT interval prolongation.

Drug discovery today·2001

Dextromethorphan and dextrorphan show promise for neuroprotection and epilepsy treatment by inhibiting N-methyl-D-aspartate (NMDA) receptors. These compounds offer potential therapeutic benefits beyond their common use as cough suppressants.

Area of Science:

Pharmacology
Neuroscience
Medicinal Chemistry

Background:

Dextromethorphan, a cough suppressant, lacks opioid receptor affinity.
Recent research highlights potential neuroprotective and antiepileptic effects of dextromethorphan and its derivative, dextrorphan.
These effects stem from interactions with specific ion channels in the nervous system.

Purpose of the Study:

To explore the neuroprotective and antiepileptic properties of dextromethorphan and dextrorphan.
To elucidate the mechanism of action underlying these novel therapeutic potentials.
To assess the role of ion channel inhibition in their anticonvulsant and neuroprotective activities.

Main Methods:

In vitro studies investigating receptor binding and cellular effects.

Related Experiment Videos

Animal experiments to evaluate anticonvulsant and neuroprotective efficacy.

Analysis of clinical case studies for therapeutic evidence.

Main Results:

Dextromethorphan and dextrorphan exhibit inhibitory effects on N-methyl-D-aspartate (NMDA) receptor channels.
They also modulate voltage-operated calcium and sodium channels with varying potencies.
Evidence from preclinical and limited clinical data supports their neuroprotective and antiepileptic potential.

Conclusions:

NMDA receptor channel inhibition is the primary mechanism for the anticonvulsant and neuroprotective actions.
Dextromethorphan and dextrorphan represent promising therapeutic agents for neurological disorders.
Further research is warranted to fully explore their clinical applications.